ASG-22CE
Phase 2Small molecule
AstellasASG-22CE is one of 23 small molecule programs targeting Radiation Therapy. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
23 competitors in Radiation Therapy
#DrugCompanyPhaseTrials
1Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Adrucil
EElorac, Inc.
Phase 3
Eloxatin
TevaPhase 3
Oncovin
Eli LillyPhase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Adriamycin
PfizerPhase 3
Nubeqa
BayerPhase 3
Cosmegen
RRECORDATI GROUP
Phase 3
Taxol
TevaPhase 2
Androgen Deprivation Therapy
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Malignant Solid Tumors1 trial
Radiation Therapy1 trial
Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)
Recruiting·—·Phase 2·NCT05879653·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ASG-22CE. EMBL-EBI & Wellcome Sanger Institute.
- [4]